Bioavailability of oral curcumin ingestion

A randomized, double-blind, parallel study to compare the relative absorption of UltraSOL Curcumin and Curcumin reference product

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN83602901

Enrollment

Registered

2017-03-21

Start date

2016-08-25

Completion date

Unknown

Last updated

2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bioavailability of two different oral curcumin formulations Not Applicable

Interventions

Subjects will be randomised to receive one of two curcumin supplements: Curcumin standard formulation (1800 mg) or UltraSOL Curcumin (376 mg), administered with a glass of water. After a 7-day washout

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Normal healthy individuals 2. Age 18-55 3. Males and females 4. Must be able to perform required testing 5. Participants agreed to sign an informed consent form

Exclusion criteria

Exclusion criteria: 1. Pregnancy 2. Use of prescription medications 3. Gastrointestinal conditions 4. Diabetics 5. Alcohol and/or substance abuse history, and/or allergies to turmeric or curcumin 6. Subjects consuming any foods or supplements containing curcumin

Design outcomes

Primary

Measure	Time frame
Plasma levels of major curcuminoids (curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin) will be evaluated at 0, 1, 2, 3, 4, 5, 6, 8 and 12 hours and 24 h. Peak plasma concentrations (TMax), areas under the plasma concentration-time curves (AUC0-6h, AUC0-12h and AUC0-24h), CMax and t max will be calculated. Relative absorption at 24h time point is helpful to observe normalization and safety of the product	—

Measure

Time frame

Plasma levels of major curcuminoids (curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin) will be evaluated at 0, 1, 2, 3, 4, 5, 6, 8 and 12 hours and 24 h. Peak plasma concentrations (TMax), areas under the plasma concentration-time curves (AUC0-6h, AUC0-12h and AUC0-24h), CMax and t max will be calculated. Relative absorption at 24h time point is helpful to observe normalization and safety of the product

—

Countries

United States of America

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026